LT2632451T - Malononitrilamidų panaudojimas esant neuropatiniam skausmui - Google Patents

Malononitrilamidų panaudojimas esant neuropatiniam skausmui

Info

Publication number
LT2632451T
LT2632451T LTEP11784418.3T LT11784418T LT2632451T LT 2632451 T LT2632451 T LT 2632451T LT 11784418 T LT11784418 T LT 11784418T LT 2632451 T LT2632451 T LT 2632451T
Authority
LT
Lithuania
Prior art keywords
malononitrilamides
neuropathic pain
neuropathic
pain
Prior art date
Application number
LTEP11784418.3T
Other languages
English (en)
Lithuanian (lt)
Inventor
Birgit Hasse
Guido Koopmans
Original Assignee
Algiax Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algiax Pharmaceuticals Gmbh filed Critical Algiax Pharmaceuticals Gmbh
Publication of LT2632451T publication Critical patent/LT2632451T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/164Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LTEP11784418.3T 2010-10-29 2011-10-28 Malononitrilamidų panaudojimas esant neuropatiniam skausmui LT2632451T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40819510P 2010-10-29 2010-10-29
EP10014122 2010-10-29
PCT/EP2011/005452 WO2012055567A2 (en) 2010-10-29 2011-10-28 Use of malononitrilamides in neuropathic pain

Publications (1)

Publication Number Publication Date
LT2632451T true LT2632451T (lt) 2018-02-12

Family

ID=44992853

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP11784418.3T LT2632451T (lt) 2010-10-29 2011-10-28 Malononitrilamidų panaudojimas esant neuropatiniam skausmui

Country Status (16)

Country Link
US (2) US20130217737A1 (OSRAM)
EP (1) EP2632451B1 (OSRAM)
JP (1) JP6257326B2 (OSRAM)
CN (1) CN103179962B (OSRAM)
CA (1) CA2814371C (OSRAM)
DK (1) DK2632451T3 (OSRAM)
ES (1) ES2655084T3 (OSRAM)
HR (1) HRP20171848T1 (OSRAM)
HU (1) HUE034890T2 (OSRAM)
LT (1) LT2632451T (OSRAM)
NO (1) NO2632451T3 (OSRAM)
PL (1) PL2632451T3 (OSRAM)
PT (1) PT2632451T (OSRAM)
RS (1) RS56713B1 (OSRAM)
SI (1) SI2632451T1 (OSRAM)
WO (1) WO2012055567A2 (OSRAM)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
US9642915B2 (en) 2012-05-07 2017-05-09 Cellix Bio Private Limited Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
CA2872975A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
JP2015518855A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 粘膜炎の治療のための組成物および方法
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
ES2797624T3 (es) 2012-05-23 2020-12-03 Cellix Bio Private Ltd Composición para el tratamiento de la enfermedad inflamatoria intestinal
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (en) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
AU2014276346A1 (en) 2013-06-04 2015-12-24 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
WO2016051420A1 (en) 2014-09-29 2016-04-07 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
ES2905771T3 (es) 2015-01-06 2022-04-12 Cellix Bio Private Ltd Composiciones y procedimientos para el tratamiento de la inflamación y del dolor
UA123464C2 (uk) * 2016-09-24 2021-04-07 Кейбіпі Байосайєнсіз Ко., Лтд. Фармацевтична композиція, яка містить антагоніст мінералокортикоїдних рецепторів, та її застосування
ES2984690T3 (es) * 2020-06-26 2024-10-30 Algiax Pharmaceuticals Gmbh Composición de nanopartículas

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
RU2142937C1 (ru) 1990-05-18 1999-12-20 Хехст АГ Амиды органических кислот, способ их получения и фармацевтическая композиция
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2727628B1 (fr) * 1994-12-02 1997-01-10 Roussel Uclaf Application des derives de 3-cycloalkyl-propanamide a titre de medicaments analgesiques
US6566395B1 (en) * 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
GB0123571D0 (en) * 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
JP5820476B2 (ja) * 2010-08-24 2015-11-24 アルギアックス ファルマコウティカルス ゲーエムベーハーALGIAX Pharmaceuticals GmbH レフルノミドおよびマロノニトリラマイドの新規の使用

Also Published As

Publication number Publication date
CA2814371A1 (en) 2012-05-03
NO2632451T3 (OSRAM) 2018-03-17
DK2632451T3 (en) 2017-12-18
WO2012055567A2 (en) 2012-05-03
JP2013545730A (ja) 2013-12-26
HUE034890T2 (hu) 2018-03-28
PL2632451T3 (pl) 2018-04-30
US20140357722A1 (en) 2014-12-04
EP2632451A2 (en) 2013-09-04
WO2012055567A3 (en) 2012-07-05
RS56713B1 (sr) 2018-03-30
PT2632451T (pt) 2017-12-14
ES2655084T3 (es) 2018-02-16
CN103179962B (zh) 2017-03-22
JP6257326B2 (ja) 2018-01-10
CA2814371C (en) 2019-03-19
SI2632451T1 (en) 2018-02-28
HRP20171848T1 (hr) 2018-02-09
US9468615B2 (en) 2016-10-18
EP2632451B1 (en) 2017-10-18
US20130217737A1 (en) 2013-08-22
CN103179962A (zh) 2013-06-26

Similar Documents

Publication Publication Date Title
PL2632451T3 (pl) Zastosowanie malononitryloamidów w bólu neuropatycznym
IL249669A0 (en) Converted 5-fluoro-1h-pyrazolopyridines and their use
IL221511A (en) Arilatriazolones associated with bis aryl and their use
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
IL226231A0 (en) A formulation of lacosamide that is administered once a day
ZA201208173B (en) Peptices and their use
ZA201309364B (en) Cannabinoids for use in the treatment of neuropathic pain
ZA201300930B (en) St-246 liquid formulations and methods
ZA201303773B (en) Compounds and their use
PL2521445T3 (pl) Preparat i jego zastosowanie
ZA201209666B (en) Salts and polymorhs of dexrabeprazole
PL2552440T3 (pl) Nowa kombinacja i zastosowanie
PL2648715T3 (pl) Mieszaniny karnozyny-kwasu hialuronowego i ich zastosowanie
PT2563806E (pt) Leucolectinas humanas e suas utilizações
EP2595594A4 (en) MASSAGER
TWM385326U (en) Structure of side-view endoscope
TWM388919U (en) Structure of endoscope
HU1000688D0 (en) Use of trifluoro-phal
GB201009194D0 (en) Treatment of pain
GB201005511D0 (en) Compounds and their use
GB201000305D0 (en) Compounds and their use
GB201020848D0 (en) Compounds and their use
GB201000307D0 (en) Compounds and their use
GB201000308D0 (en) Compounds and their use
GB201000309D0 (en) Compounds and their use